Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) hit a new 52-week low during trading on Thursday . The company traded as low as $3.34 and last traded at $3.42, with a volume of 6948 shares. The stock had previously closed at $4.22.

The stock has a market capitalization of $4.47 million, a P/E ratio of -0.10 and a beta of 1.30.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its quarterly earnings data on Friday, November 9th. The company reported ($5.70) EPS for the quarter, topping the Zacks’ consensus estimate of ($6.10) by $0.40. Analysts anticipate that Tonix Pharmaceuticals Holding Corp will post -23.5 earnings per share for the current fiscal year.

An institutional investor recently raised its position in Tonix Pharmaceuticals stock. Renaissance Technologies LLC boosted its holdings in shares of Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) by 66.0% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 179,300 shares of the company’s stock after acquiring an additional 71,300 shares during the quarter. Renaissance Technologies LLC owned 2.15% of Tonix Pharmaceuticals worth $798,000 at the end of the most recent quarter. 5.56% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this report on another website, it was illegally copied and reposted in violation of United States & international copyright and trademark law. The legal version of this report can be read at https://www.dailypolitical.com/2018/12/08/tonix-pharmaceuticals-tnxp-sets-new-12-month-low-at-3-34.html.

About Tonix Pharmaceuticals (NASDAQ:TNXP)

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and to improve biodefense. Its lead product candidate is TNX-102 SL or Tonmya that is designed as a bedtime administration for posttraumatic stress disorder (PTSD), which is in Phase 3 study in the military-related PTSD population.

Further Reading: Price to Earnings Ratio (PE), For Valuing Stocks

Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.